AG˹ٷ

STOCK TITAN

[6-K] Haleon plc American Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary

Haleon plc purchased 856,760 ordinary shares of £0.01 each for cancellation under the second tranche of its share buyback programme announced 31 July 2025. The purchases were executed on 08 August 2025 on the London Stock Exchange at prices between 353.5000p and 356.1000p, with a volume-weighted average price of 354.6173p.

Following settlement the company's registered share capital is 8,979,735,788 ordinary shares, of which 3,880,205 are held as treasury shares, leaving 8,975,855,583 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on Haleon's investor website.

Haleon plc ha acquistato 856.760 azioni ordinarie del valore nominale di £0,01 ciascuna da annullare, nell'ambito della seconda tranche del programma di riacquisto azionario annunciato il 31 luglio 2025. Gli acquisti sono stati eseguiti l'08 agosto 2025 alla Borsa di Londra a prezzi compresi tra 353.5000p e 356.1000p, con un prezzo medio ponderato per volume di 354.6173p.

A seguito del regolamento, il capitale sociale registrato della società è di 8.979.735.788 azioni ordinarie, di cui 3.880.205 sono detenute in tesoreria, lasciando 8.975.855.583 azioni ordinarie con diritto di voto. Una ripartizione completa delle singole operazioni è disponibile tramite il link RNS fornito e sul sito investitori di Haleon.

Haleon plc compró 856.760 acciones ordinarias de £0,01 cada una para su cancelación, en el marco de la segunda fase de su programa de recompra de acciones anunciado el 31 de julio de 2025. Las compras se ejecutaron el 08 de agosto de 2025 en la Bolsa de Londres a precios entre 353.5000p y 356.1000p, con un precio medio ponderado por volumen de 354.6173p.

Tras la liquidación, el capital social registrado de la compañía es de 8.979.735.788 acciones ordinarias, de las cuales 3.880.205 se mantienen como acciones en tesorería, quedando 8.975.855.583 acciones ordinarias con derecho a voto. Un desglose completo de las operaciones individuales está disponible a través del enlace RNS proporcionado y en la web de inversores de Haleon.

Haleon plc� 2025� 7� 31일에 발표� 자사� 매입 프로그램� � 번째 트랜치에 따라 취소� 위해 주당 액면가 £0.01� 보통� 856,760주를 매수했습니다. 해당 매수� 2025� 8� 8� 런던 증권거래소에� 353.5000p356.1000p 사이� 가격으� 체결되었으며, 거래� 가� 평균 가격은 354.6173p옶습니�.

결제 � 회사� 등록 자본은 8,979,735,788 보통주이�, 그중 3,880,205주는 자사주로 보유되어 의결권이 있는 보통주는 8,975,855,583주입니다. 개별 거래 내역 전체� 제공� RNS 링크왶 Haleon� 투자� 웹사이트에서 확인� � 있습니다.

Haleon plc a acheté 856 760 actions ordinaires d'une valeur nominale de £0,01 chacune en vue de leur annulation, dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025. Les achats ont été exécutés le 08 août 2025 à la Bourse de Londres à des prix compris entre 353.5000p et 356.1000p, avec un prix moyen pondéré par le volume de 354.6173p.

Après règlement, le capital social enregistré de la société est de 8.979.735.788 actions ordinaires, dont 3.880.205 sont détenues en actions propres, laissant 8.975.855.583 actions ordinaires avec droit de vote. Une ventilation complète des transactions individuelles est disponible via le lien RNS fourni et sur le site investisseurs de Haleon.

Haleon plc hat 856.760 Stammaktien à £0,01 zur Streichung im Rahmen der zweiten Tranche seines am 31. Juli 2025 angekündigten Aktienrückkaufprogramms erworben. Die Käufe wurden am 08. August 2025 an der London Stock Exchange zu Preisen zwischen 353.5000p und 356.1000p ausgeführt, mit einem volumen­gewichteten Durchschnittspreis von 354.6173p.

Nach der Abwicklung beträgt das eingetragene Stammkapital der Gesellschaft 8.979.735.788 Stammaktien, davon sind 3.880.205 als eigene Aktien gehalten, sodass 8.975.855.583 Stammaktien stimmberechtigt sind. Eine vollständige Aufschlüsselung der einzelnen Transaktionen ist über den bereitgestellten RNS-Link und auf der Investorenseite von Haleon verfügbar.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small executed tranche of announced buyback; immaterial to outstanding share count and per-share metrics at company scale.

The transaction shows active execution of the second tranche of the company’s buyback programme, with 856,760 shares bought at a VWAP of 354.6173p. Relative to the registered share capital of 8.98 billion shares, this tranche represents a de minimis reduction in share count and is unlikely to meaningfully affect EPS or ownership thresholds. The announcement and RNS trade breakdown provide transparency on execution; investors should treat this as routine return-of-capital activity rather than a material capital-structure change.

TL;DR: Execution of the buyback tranche demonstrates governance follow-through; the scale of purchases is negligible versus total shares.

The filing documents compliance with disclosure rules and supplies post-settlement share counts and treasury holdings. Reporting the highest, lowest and VWAP prices and publishing a full trade breakdown follows market best practice. Given the tiny percentage reduction in outstanding shares, this tranche does not materially alter shareholder voting dynamics or regulatory notification thresholds, though it reflects management's ongoing capital allocation choices under the announced programme.

Haleon plc ha acquistato 856.760 azioni ordinarie del valore nominale di £0,01 ciascuna da annullare, nell'ambito della seconda tranche del programma di riacquisto azionario annunciato il 31 luglio 2025. Gli acquisti sono stati eseguiti l'08 agosto 2025 alla Borsa di Londra a prezzi compresi tra 353.5000p e 356.1000p, con un prezzo medio ponderato per volume di 354.6173p.

A seguito del regolamento, il capitale sociale registrato della società è di 8.979.735.788 azioni ordinarie, di cui 3.880.205 sono detenute in tesoreria, lasciando 8.975.855.583 azioni ordinarie con diritto di voto. Una ripartizione completa delle singole operazioni è disponibile tramite il link RNS fornito e sul sito investitori di Haleon.

Haleon plc compró 856.760 acciones ordinarias de £0,01 cada una para su cancelación, en el marco de la segunda fase de su programa de recompra de acciones anunciado el 31 de julio de 2025. Las compras se ejecutaron el 08 de agosto de 2025 en la Bolsa de Londres a precios entre 353.5000p y 356.1000p, con un precio medio ponderado por volumen de 354.6173p.

Tras la liquidación, el capital social registrado de la compañía es de 8.979.735.788 acciones ordinarias, de las cuales 3.880.205 se mantienen como acciones en tesorería, quedando 8.975.855.583 acciones ordinarias con derecho a voto. Un desglose completo de las operaciones individuales está disponible a través del enlace RNS proporcionado y en la web de inversores de Haleon.

Haleon plc� 2025� 7� 31일에 발표� 자사� 매입 프로그램� � 번째 트랜치에 따라 취소� 위해 주당 액면가 £0.01� 보통� 856,760주를 매수했습니다. 해당 매수� 2025� 8� 8� 런던 증권거래소에� 353.5000p356.1000p 사이� 가격으� 체결되었으며, 거래� 가� 평균 가격은 354.6173p옶습니�.

결제 � 회사� 등록 자본은 8,979,735,788 보통주이�, 그중 3,880,205주는 자사주로 보유되어 의결권이 있는 보통주는 8,975,855,583주입니다. 개별 거래 내역 전체� 제공� RNS 링크왶 Haleon� 투자� 웹사이트에서 확인� � 있습니다.

Haleon plc a acheté 856 760 actions ordinaires d'une valeur nominale de £0,01 chacune en vue de leur annulation, dans le cadre de la deuxième tranche de son programme de rachat d'actions annoncé le 31 juillet 2025. Les achats ont été exécutés le 08 août 2025 à la Bourse de Londres à des prix compris entre 353.5000p et 356.1000p, avec un prix moyen pondéré par le volume de 354.6173p.

Après règlement, le capital social enregistré de la société est de 8.979.735.788 actions ordinaires, dont 3.880.205 sont détenues en actions propres, laissant 8.975.855.583 actions ordinaires avec droit de vote. Une ventilation complète des transactions individuelles est disponible via le lien RNS fourni et sur le site investisseurs de Haleon.

Haleon plc hat 856.760 Stammaktien à £0,01 zur Streichung im Rahmen der zweiten Tranche seines am 31. Juli 2025 angekündigten Aktienrückkaufprogramms erworben. Die Käufe wurden am 08. August 2025 an der London Stock Exchange zu Preisen zwischen 353.5000p und 356.1000p ausgeführt, mit einem volumen­gewichteten Durchschnittspreis von 354.6173p.

Nach der Abwicklung beträgt das eingetragene Stammkapital der Gesellschaft 8.979.735.788 Stammaktien, davon sind 3.880.205 als eigene Aktien gehalten, sodass 8.975.855.583 Stammaktien stimmberechtigt sind. Eine vollständige Aufschlüsselung der einzelnen Transaktionen ist über den bereitgestellten RNS-Link und auf der Investorenseite von Haleon verfügbar.

UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
 
FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of August 2025
 
Commission File Number: 001-41411
 
Haleon plc
(Translation of registrant’s name into English)
 
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address of principal executive offices)
 
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
 
 
Form 20-F
 
Form 40-F
 
 
 
 
 
 
EXHIBIT INDEX
 
Exhibit Number
Description
99.1
11 August 2025 - “Transaction in Own Shares”
 
 
 
 
99.1
 
 
Haleon plc: Transaction in own shares
 
11 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 856,760 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.
 
 
London Stock Exchange
CBOE (UK)/BXE
CBOE (UK)/CXE
Date of purchase:
08 August 2025
08 August 2025
08 August 2025
Number of Shares purchased:
856,760
-
-
Highest price paid per Share (p):
356.1000
-
-
Lowest price paid per Share (p):
353.5000
-
-
Volume weighted average price paid per Share (p):
354.6173
-
-
 
Following the settlement of the above, the Company's registered share capital is 8,979,735,788 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,975,855,583 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
 
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
 
http://www.rns-pdf.londonstockexchange.com/rns/6867U_1-2025-8-8.pdf
 
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
 
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
 
Enquiries
 
 
Investors
Media
 
Jo Russell  
+44 7787 392441
Zoë Bird
+44 7736 746167
Rakesh Patel     
+44 7552 484646
Victoria Durman
+44 7894 505730
 
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
 
For more information, please visit www.haleon.com
 
 
 
 
SIGNATURE
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
HALEON PLC
(Registrant)
 
Date: August 11, 2025
By:
/s/ Amanda Mellor
 
 
Name:
Amanda Mellor
 
 
Title:
Company Secretary

FAQ

What did Haleon (HLN) announce in this Form 6-K?

Haleon purchased 856,760 ordinary shares on 08 August 2025 under the second tranche of its buyback programme; VWAP 354.6173p; high 356.1000p; low 353.5000p.

How many shares does Haleon have after the purchase (HLN)?

Registered share capital: 8,979,735,788 ordinary shares; 3,880,205 held as treasury; 8,975,855,583 ordinary shares carry voting rights.

On which venue were the shares purchased?

The shares listed in this announcement were purchased on the London Stock Exchange on 08 August 2025; no purchases were recorded on CBOE (UK)/BXE or CBOE (UK)/CXE for this tranche.

Is a detailed breakdown of the individual trades available?

Yes. A full breakdown is available via the RNS PDF link provided in the announcement and on Haleon's investor website.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute, or form part of, an offer or solicitation of an offer for securities in any jurisdiction.
Haleon

NYSE:HLN

HLN Rankings

HLN Latest News

HLN Latest SEC Filings

HLN Stock Data

43.59B
4.47B
0.02%
12.82%
0.39%
Drug Manufacturers - Specialty & Generic
Healthcare
United Kingdom
Weybridge